Aerovate Therapeutics (AVTE) Reports 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Trial Jun 17, 2024 08:32AM
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension Jun 17, 2024 08:32AM
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference May 21, 2024 04:15PM
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights May 13, 2024 04:30PM
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference Mar 27, 2024 09:20AM


Mar 25, 2024 04:10PM Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Mar 6, 2024 08:02AM Aerovate Therapeutics (AVTE) Appoints Habib Dable as Board Chair
Mar 6, 2024 08:00AM Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Nov 20, 2023 04:45PM Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmo
Nov 13, 2023 08:00AM Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
Aug 14, 2023 08:00AM Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
Jul 11, 2023 05:00PM Aerovate Therapeutics (AVTE) Appoints Habib Dable To Its Board
Jul 11, 2023 05:00PM Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
Jun 1, 2023 08:00AM Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
May 22, 2023 01:17PM Aerovate Therapeutics (AVTE) Presents Nonclinical Pharmacokinetic Data in Support of AV-101
May 22, 2023 01:15PM Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conf
May 15, 2023 04:05PM Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Mar 29, 2023 04:50PM Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
Mar 2, 2023 08:00AM Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
Jan 23, 2023 08:00AM Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
Nov 17, 2022 07:45AM Aerovate Therapeutics (AVTE) Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Nov 17, 2022 07:45AM Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Nov 17, 2022 07:45AM Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Nov 14, 2022 07:45AM Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
Nov 14, 2022 07:45AM Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
Oct 18, 2022 08:03AM Aerovate Therapeutics (AVTE) Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design
Oct 18, 2022 08:00AM Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Aug 15, 2022 07:50AM Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
Jun 2, 2022 08:00AM Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
May 16, 2022 05:16PM Aerovate Therapeutics (AVTE) Reports Phase 1 Data for AV-101
May 16, 2022 05:15PM Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 16, 2022 08:00AM Aerovate Therapeutics Announces First Quarter 2022 Financial Results